Breaking News
Investing Pro 0
Cyber Monday Extended SALE: Up to 60% OFF InvestingPro+ CLAIM OFFER

Myovant Sciences Rejects Sumitovant/Sumitomo Pharma Buyout Offer Of $2.5B

Stock Markets Oct 03, 2022 13:11
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. Myovant Sciences Rejects Sumitovant/Sumitomo Pharma Buyout Offer Of $2.5B
 
SSUMY
+1.44%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
MYOV
+0.06%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

  • Myovant Sciences Ltd (NYSE: MYOV) rejected a $2.5 billion takeover offer from Sumitovant Biopharma Ltd and Sumitomo Pharma Co., Ltd, saying that the offer undervalues the company.
  • Myovant Sciences confirmed that it received a preliminary, non-binding proposal from Sumitovant Biopharma and Sumitomo Pharma Co., Ltd. to acquire the remaining shares of the Company that Sumitovant does not currently hold for a price of $22.75 per share in cash.
  • Sumitovant currently holds about 52% of the outstanding shares of the company.
  • Myovant said its Special Committee determined that the offer significantly undervalues the company and, therefore, is not in the best interests of the company or its minority shareholders.
  • The Special Committee remains open to considering any improved proposal that reflects the full and fair value of the company and is otherwise in the best interests of the company and its shareholders and is prepared to engage further with Sumitomo regarding any such proposal, Myovant said in a statement.
  • In a separate press release, Sumitomo Pharma said the proposed transaction, if completed, would result in Myovant being delisted from the NYSE.
  • According to Sumitomo Pharma, the proposed acquisition consideration represents an equity value for Myovant of $2.4 billion and an enterprise value of $2.5 billion.
  • The proposed per-share consideration represents a premium of about 27% to Myovant's closing share price on September 30.
  • Price Action: MYOV shares are up 29.1% at $23.18 during the premarket session on the last check Monday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Myovant Sciences Rejects Sumitovant/Sumitomo Pharma Buyout Offer Of $2.5B
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email